vs

Side-by-side financial comparison of FTC Solar, Inc. (FTCI) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $32.9M, roughly 1.1× FTC Solar, Inc.). FTC Solar, Inc. runs the higher net margin — -110.7% vs -304.2%, a 193.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 148.9%). FTC Solar, Inc. produced more free cash flow last quarter ($-8.4M vs $-47.3M). Over the past eight quarters, FTC Solar, Inc.'s revenue compounded faster (61.6% CAGR vs 60.5%).

FTC Solar, Inc. is a leading global provider of advanced solar tracker systems, associated components, and supporting software for solar projects. It serves utility-scale, commercial, and industrial solar segments across key global markets, helping customers boost energy generation efficiency and lower overall project costs.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

FTCI vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$32.9M
FTCI
Growing faster (revenue YoY)
RXRX
RXRX
+532.8% gap
RXRX
681.7%
148.9%
FTCI
Higher net margin
FTCI
FTCI
193.5% more per $
FTCI
-110.7%
-304.2%
RXRX
More free cash flow
FTCI
FTCI
$38.9M more FCF
FTCI
$-8.4M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
FTCI
FTCI
Annualised
FTCI
61.6%
60.5%
RXRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FTCI
FTCI
RXRX
RXRX
Revenue
$32.9M
$35.5M
Net Profit
$-36.4M
$-108.1M
Gross Margin
14.9%
59.8%
Operating Margin
-17.2%
-304.8%
Net Margin
-110.7%
-304.2%
Revenue YoY
148.9%
681.7%
Net Profit YoY
-197.4%
39.6%
EPS (diluted)
$-2.31
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FTCI
FTCI
RXRX
RXRX
Q4 25
$32.9M
$35.5M
Q3 25
$26.0M
$5.2M
Q2 25
$20.0M
$19.2M
Q1 25
$20.8M
$14.7M
Q4 24
$13.2M
$4.5M
Q3 24
$10.1M
$26.1M
Q2 24
$11.4M
$14.4M
Q1 24
$12.6M
$13.8M
Net Profit
FTCI
FTCI
RXRX
RXRX
Q4 25
$-36.4M
$-108.1M
Q3 25
$-23.9M
$-162.3M
Q2 25
$-15.4M
$-171.9M
Q1 25
$-3.8M
$-202.5M
Q4 24
$-12.2M
$-178.9M
Q3 24
$-15.4M
$-95.8M
Q2 24
$-12.2M
$-97.5M
Q1 24
$-8.8M
$-91.4M
Gross Margin
FTCI
FTCI
RXRX
RXRX
Q4 25
14.9%
59.8%
Q3 25
6.1%
-183.8%
Q2 25
-19.6%
-4.9%
Q1 25
-16.6%
-48.0%
Q4 24
-29.1%
-181.4%
Q3 24
-42.5%
53.7%
Q2 24
-20.5%
36.2%
Q1 24
-16.7%
19.1%
Operating Margin
FTCI
FTCI
RXRX
RXRX
Q4 25
-17.2%
-304.8%
Q3 25
-29.6%
-3327.6%
Q2 25
-57.5%
-916.8%
Q1 25
-50.8%
-1297.9%
Q4 24
-101.7%
-4042.4%
Q3 24
-147.8%
-377.1%
Q2 24
-104.3%
-697.4%
Q1 24
-99.3%
-698.4%
Net Margin
FTCI
FTCI
RXRX
RXRX
Q4 25
-110.7%
-304.2%
Q3 25
-92.0%
-3135.3%
Q2 25
-77.2%
-894.2%
Q1 25
-18.4%
-1373.3%
Q4 24
-92.7%
-3935.5%
Q3 24
-151.5%
-367.5%
Q2 24
-107.1%
-676.6%
Q1 24
-69.7%
-662.4%
EPS (diluted)
FTCI
FTCI
RXRX
RXRX
Q4 25
$-2.31
$-0.17
Q3 25
$-1.61
$-0.36
Q2 25
$-1.18
$-0.41
Q1 25
$-0.58
$-0.50
Q4 24
$-0.95
$-0.56
Q3 24
$-1.21
$-0.34
Q2 24
$-0.97
$-0.40
Q1 24
$-0.70
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FTCI
FTCI
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$21.1M
$743.3M
Total DebtLower is stronger
$9.9M
$9.6M
Stockholders' EquityBook value
$-43.0M
$1.1B
Total Assets
$111.8M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FTCI
FTCI
RXRX
RXRX
Q4 25
$21.1M
$743.3M
Q3 25
$24.4M
$659.8M
Q2 25
$3.5M
$525.1M
Q1 25
$5.9M
$500.5M
Q4 24
$11.2M
$594.4M
Q3 24
$8.3M
$427.6M
Q2 24
$10.8M
$474.3M
Q1 24
$14.0M
$296.3M
Total Debt
FTCI
FTCI
RXRX
RXRX
Q4 25
$9.9M
$9.6M
Q3 25
$16.6M
$11.9M
Q2 25
$10.9M
$14.2M
Q1 25
$10.2M
$16.4M
Q4 24
$9.5M
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
FTCI
FTCI
RXRX
RXRX
Q4 25
$-43.0M
$1.1B
Q3 25
$-13.7M
$1.0B
Q2 25
$9.0M
$919.1M
Q1 25
$15.5M
$933.9M
Q4 24
$19.0M
$1.0B
Q3 24
$30.4M
$524.6M
Q2 24
$44.2M
$584.4M
Q1 24
$55.2M
$401.2M
Total Assets
FTCI
FTCI
RXRX
RXRX
Q4 25
$111.8M
$1.5B
Q3 25
$111.5M
$1.4B
Q2 25
$83.0M
$1.3B
Q1 25
$84.1M
$1.3B
Q4 24
$89.9M
$1.4B
Q3 24
$91.7M
$726.5M
Q2 24
$100.3M
$775.9M
Q1 24
$115.0M
$557.8M
Debt / Equity
FTCI
FTCI
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
1.20×
0.02×
Q1 25
0.65×
0.02×
Q4 24
0.50×
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FTCI
FTCI
RXRX
RXRX
Operating Cash FlowLast quarter
$-8.0M
$-46.1M
Free Cash FlowOCF − Capex
$-8.4M
$-47.3M
FCF MarginFCF / Revenue
-25.7%
-133.1%
Capex IntensityCapex / Revenue
1.3%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-34.6M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FTCI
FTCI
RXRX
RXRX
Q4 25
$-8.0M
$-46.1M
Q3 25
$-14.6M
$-117.4M
Q2 25
$-2.3M
$-76.4M
Q1 25
$-8.5M
$-132.0M
Q4 24
$-16.7M
$-115.4M
Q3 24
$-2.4M
$-59.2M
Q2 24
$-3.8M
$-82.2M
Q1 24
$-11.9M
$-102.3M
Free Cash Flow
FTCI
FTCI
RXRX
RXRX
Q4 25
$-8.4M
$-47.3M
Q3 25
$-15.1M
$-117.6M
Q2 25
$-2.5M
$-79.6M
Q1 25
$-8.6M
$-133.8M
Q4 24
$-17.0M
$-116.7M
Q3 24
$-2.6M
$-63.8M
Q2 24
$-4.5M
$-83.4M
Q1 24
$-12.3M
$-109.0M
FCF Margin
FTCI
FTCI
RXRX
RXRX
Q4 25
-25.7%
-133.1%
Q3 25
-57.9%
-2272.5%
Q2 25
-12.4%
-413.9%
Q1 25
-41.2%
-907.4%
Q4 24
-128.6%
-2567.7%
Q3 24
-25.6%
-244.6%
Q2 24
-39.2%
-578.5%
Q1 24
-97.6%
-789.9%
Capex Intensity
FTCI
FTCI
RXRX
RXRX
Q4 25
1.3%
3.5%
Q3 25
1.7%
4.7%
Q2 25
0.9%
16.4%
Q1 25
0.4%
12.4%
Q4 24
2.2%
28.6%
Q3 24
2.2%
17.5%
Q2 24
6.1%
8.2%
Q1 24
3.4%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FTCI
FTCI

Products$26.2M80%
Services$6.7M20%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons